Lung Transplant Achieves 100% One-Year Survival in Select Patients with Terminal Lung-Limited NSCLC, Landmark DREAM Registry Study Shows

A landmark study from the Northwestern Medicine Canning Thoracic Institute (搜索)搜索该词条, published July 8, 2026 in JAMA, demonstrates that double-lung transplantation can dramatically extend survival in a highly selected group of patients with medically refractory, lung-limited stage IV non-small cell lung cancer (搜索)搜索该疾病 (NSCLC). The findings represent what investigators describe as a "new model of transplant oncology."

The study evaluated outcomes from the Double Lung Transplant Registry for Lung-Limited Malignancies — the DREAM registry — a pioneering program at Northwestern Medicine, currently the only known health system in the United States with a dedicated lung transplant program for patients with advanced lung cancers who have exhausted all other treatment options.

Key survival findings

Among 98 patients with stage IV lung cancer rigorously confirmed to be confined to the lungs, 17 underwent double-lung transplant and 81 met transplant eligibility criteria but received medical management alone due to nonbiologic barriers such as logistical, financial, or geographic factors.

The one-year survival rate was 100% for the 17 transplanted patients, compared with 41% for the 81 patients treated with medical therapies alone. When compared with 306 patients without cancer who underwent lung transplant for end-stage pulmonary diseases such as cystic fibrosis, COPD, or pulmonary hypertension, the cancer transplant cohort again showed superior early outcomes: 100% versus 88% one-year posttransplant survival.

"This work changes what we can imagine for a highly selected group of patients who were previously considered beyond the reach of curative-intent intervention," said co-corresponding author Ankit Bharat, MD, chief of thoracic surgery and director of the Canning Thoracic Institute. "We are not saying lung transplant is appropriate for every patient with stage IV lung cancer. We are saying that when the cancer is rigorously proven to be confined to the lungs, when standard therapies have been exhausted, and when the lungs themselves have become the life-limiting organ, transplantation may offer a new path forward."

A biologically distinct clinical scenario

Lung cancer remains the leading cause of cancer-related deaths in the United States, claiming more lives than colon, breast, and prostate cancers combined. While most patients with stage IV lung cancer have disease that has spread beyond the lungs, a subset develops advanced NSCLC that remains anatomically confined to the lungs even as it progresses throughout both organs and causes respiratory failure. For these patients, the immediate cause of death is often not widespread systemic cancer but progressive failure of cancer-filled lungs.

"This is a biologically distinct clinical scenario. These patients have stage IV cancer, but the disease remains anatomically limited to the lungs," said co-corresponding author Young Kwang Chae, MD, MPH, a thoracic medical oncologist with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "In these rare select group of patients, DREAM provides us a disciplined, scientifically rigorous way to ask whether removing the organ containing all visible disease can change the natural history of an otherwise fatal condition."

Rigorous staging and surgical innovation

Lung cancer has historically been considered a relative contraindication to transplantation due to concerns about rapid recurrence in the donor organ. The DREAM protocol addresses this through comprehensive contemporary staging — including advanced imaging and systematic invasive mediastinal evaluation — to confirm disease is truly lung-limited before listing. Transplant was considered only after patients had medically refractory disease despite available systemic therapies and consideration for clinical trials.

The surgical strategy was redesigned to minimize the risk of cancer dissemination. "This innovative technique involves putting the patient on heart and lung bypass, delicately taking both cancer-ridden lungs out at the same time along with the lymph nodes, washing the airways and the chest cavity to clear the cancer, and then putting new lungs in," Bharat explained. "These patients can have billions of cancer cells in the lungs, so we must be extremely meticulous to not let a single cell spill into the patient's chest cavity or blood stream."

The team also employed single-cell transcriptomic analyses on explanted tumors, revealing profoundly resistant cancer-cell populations relying on different resistance pathways. "That helps explain why chemotherapy, immunotherapy and other systemic therapies could no longer meaningfully control the disease and why replacing the diseased lungs may be the only realistic option to extend life for these carefully selected patients," Bharat said.

"The paradigm shift is not simply that transplant was performed for lung cancer. The shift is that transplantation was embedded within a complete scientific framework — rigorous staging, proof of lung-limited disease, transplant-specific operative innovation, intensive surveillance and molecular analysis of the explanted tumors," said co-corresponding author G.R. Scott Budinger, MD, chief of pulmonary and critical care medicine at the Canning Thoracic Institute.

Recovery, recurrence, and limitations

Postoperative outcomes were comparable between groups. Median hospital length of stay was 14 days for patients transplanted for stage IV lung cancer versus 16 days for transplant recipients without cancer.

During follow-up, four of the 17 transplant recipients experienced cancer recurrence and were treated with local and systemic therapies including surgery, radiation, chemotherapy, and immunotherapy. By the study's end in January 2026, two of the 17 transplant recipients had died.

The authors emphasize that longer follow-up is essential to define the durability of disease control, the risk of late recurrence, and long-term quality of life after transplant. "This is not a claim that transplant restores normal life expectancy, and it's not a blanket indication for stage IV lung cancer. It's evidence that a carefully selected group of patients facing otherwise poor near-term survival may have an opportunity for meaningful additional life — that's why this work matters," Bharat said.

Program scope

To date, Northwestern Medicine surgeons have performed more than 50 lung transplants for patients with advanced lung cancers through the DREAM program. Since the Lung Transplant Program's inception in 2014, the center has completed more than 700 lung transplant procedures for end-stage lung diseases, with a median wait time of just three days — among the shortest in the United States.